Nektar Therapeutics
NKTR
$56.23
-$0.39-0.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.86M | 21.81M | 11.79M | 11.18M | 10.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.86M | 21.81M | 11.79M | 11.18M | 10.46M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 10.86M | 21.81M | 11.79M | 11.18M | 10.46M |
| SG&A Expenses | 13.44M | 11.19M | 16.07M | 17.07M | 24.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.12M | 40.90M | 43.32M | 46.96M | 54.83M |
| Operating Income | -38.26M | -19.09M | -31.53M | -35.78M | -44.37M |
| Income Before Tax | -44.84M | -36.05M | -35.56M | -41.78M | -50.83M |
| Income Tax Expenses | 64.00K | 31.00K | -33.00K | -188.00K | 52.00K |
| Earnings from Continuing Operations | -44.90M | -36.08M | -35.52M | -41.59M | -50.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.90M | -36.08M | -35.52M | -41.59M | -50.88M |
| EBIT | -38.26M | -19.09M | -31.53M | -35.78M | -44.37M |
| EBITDA | -38.11M | -18.90M | -31.34M | -35.57M | -43.94M |
| EPS Basic | -1.82 | -1.78 | -1.87 | -2.95 | -3.62 |
| Normalized Basic EPS | -1.11 | -0.85 | -1.17 | -1.83 | -2.25 |
| EPS Diluted | -1.82 | -1.78 | -1.87 | -2.95 | -3.62 |
| Normalized Diluted EPS | -1.11 | -0.85 | -1.17 | -1.83 | -2.25 |
| Average Basic Shares Outstanding | 24.74M | 20.30M | 18.95M | 14.09M | 14.06M |
| Average Diluted Shares Outstanding | 24.74M | 20.30M | 18.95M | 14.09M | 14.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |